Grants and Contributions

The objective of this funding opportunity is to catalyze and support research efforts of Canadian researchers to use the available CLSA data in order to better understand how (individually and in combination) the biological, medical, psychological, social, lifestyle and/or economic aspects of people’s lives have an impact in both maintaining health and in the development of disease and disability as people age.

The Operating Grant: Methamphetamine and related psychostimulant use is expected to:

• Generate new knowledge around prevalence, incidence, and distribution of methamphetamine use in Canada
• Increase the uptake and application of synthesized knowledge in evidence-based decision-making, health care and/or health services policy and practice in this space
• Support partnerships between researchers and knowledge users to rapidly inform policies related to prevention, harm reduction, and treatment of methamphetamine use
• Address the pressing intervention-related evidence needs of knowledge users in this space
• Encourage implementation science approaches that consider sub-populations and/or the biological and social determinants of methamphetamine use

• The CIHR Institute of Infection and Immunity (CIHR-III) will offer funding for an application determined to be specifically relevant to CIHR-III broad mandate as described below:
o The Institute of Infection and Immunity (III) supports research and helps to build research capacity in the areas of infectious disease and the body's immune system.

The “Catalyst Grant: Addressing Musculoskeletal Conditions and Arthritis in Canadians” is expected to:
•Support original, high quality projects that have the potential to generate innovative research, research tools, techniques, devices, inventions, or methods that will translate into a clinical or health services improvement for Canadians within 5-7 years;
•Facilitate team formation and build patient-oriented research capacity by encouraging partnerships amongst patients, patient communities, patient organizations and health charities, researchers, health care professionals and health system decision makers or policy makers;
•Generate preliminary observations, data or knowledge to stimulate research in areas where there is a substantial burden of disease in musculoskeletal conditions and arthritis in Canada, as identified by the respective communities.

This funding opportunity is expected to:
•Catalyze patient-oriented research aligned with the SPOR Patient Engagement Framework and SPOR Capacity Development Framework by:
¿Developing partnerships amongst patients and patient communities, researchers, health care professionals and health system decision-makers or policy-makers;
¿Mobilizing the above partnerships to develop and conduct a patient-oriented research project or projects; and,
¿Informing future applications for more comprehensive patient-oriented research grants.

To provide recognition and funding to academic researchers; to provide a reliable supply of highly skilled and qualified researchers.

This funding opportunity is expected to:
•Increase Canadian capacity to measure the impact of patient-oriented research in order to demonstrate the extent of health, social and economic benefits realized through patient-oriented research;
•Increase the literature currently available on the impact of patient-oriented research in Canada in order to:
¿Enable summative evaluation and meta-analyses on the impact of patient-oriented research; and,
¿Demonstrate how patient-oriented research compares to other health research approaches in terms of the potential to translate evidence into the health care system.

The Understanding Disease Prevention and Risk Factor Modification Catalyst Grants are expected to:

• increase our understanding of factors that enable individuals to adopt or overlook known disease risk modification strategies;
• expand the evidence and further understanding that can lead to future intervention studies in prevention; and
• develop a knowledge base upon which to nuance evidence-based policy to improve the prevention of manageable diseases.

• The CIHR Institute of Nutrition, Metabolism and Diabetes (INMD) will provide funding for an application determined to be relevant to the broad INMD mandate as described below:
o CIHR-INMD supports research to enhance health in relation to diet, digestion, excretion, and metabolism; and to address causes, prevention, screening, diagnosis, treatment, support systems, and palliation for a wide range of conditions and problems associated with hormone, digestive system, kidney, and liver.
• These grants afford principal investigators an opportunity to resubmit their research proposal without the loss of momentum, staff or trainees.

This funding opportunity is expected to:

• Advance knowledge through the analysis of existing cohorts, data platforms and/or administrative datasets specific to one of the research areas above.